2 research outputs found
Eoxins : a new inflammatory pathway in childhood asthma
Background: Increased levels of leukotrienes (LTs) in exhaled
breath condensate (EBC) are associated with asthma and
bronchial hyperresponsiveness (BHR), whereas eicosanoids
generated through the 15-lipoxygenase (LO) pathway (15-
hydroxyeicosatetraenoic acid [HETE] and eoxins) have been less
studied.
Objective: We investigated whether metabolites of the 5- and
15-LO pathways in EBC are associated with childhood asthma,
asthma severity, and clinical parameters.
Methods: The present study included 131 school-aged children
(27 children with problematic severe asthma, 80 children with
mild-to-moderate asthma, and 24 healthy children) from the
Severe Asthma Recognized in Childhood study and 19 children
with other nonasthmatic chronic lung diseases. Clinical work-up
included spirometry, fractional exhaled nitric oxide
measurements, skin prick testing, and methacholine challenge.
Eicosanoids were analyzed in EBC by using mass spectrometry
and are reported as concentrations (in picograms per milliliter)
and eicosanoid/palmitic acid (PA) ratios.
Results: Eoxin C4/PA, eoxin D4/PA, eoxin E4/PA, 15-HETE/PA,
and LTC4/PA ratios were significantly increased in asthmatic
versus healthy children. Eoxin D4/PA and LTE4/PA ratios were
also significantly higher in children with BHR. A nonsignificant
trend was observed toward higher eoxin/PA ratios with
increasing asthma severity. In contrast to asthma, children with
chronic lung disease had the highest 15-HETE/PA, LTC4/PA,
LTE4/PA, and LTB4/PA ratios.
Conclusion: The results point to increased activity of the 15-LO
inflammatory pathway in childhood asthma. Mass
spectrometric analyses of EBC demonstrate that increased
eoxin levels not only accompany the increased 5-LO product
LTC4 but are also associated with BHR. These markers might
represent a new therapeutic target for asthma treatment.Background: Increased levels of leukotrienes (LTs) in exhaled
breath condensate (EBC) are associated with asthma and
bronchial hyperresponsiveness (BHR), whereas eicosanoids
generated through the 15-lipoxygenase (LO) pathway (15-
hydroxyeicosatetraenoic acid [HETE] and eoxins) have been less
studied.
Objective: We investigated whether metabolites of the 5- and
15-LO pathways in EBC are associated with childhood asthma,
asthma severity, and clinical parameters.
Methods: The present study included 131 school-aged children
(27 children with problematic severe asthma, 80 children with
mild-to-moderate asthma, and 24 healthy children) from the
Severe Asthma Recognized in Childhood study and 19 children
with other nonasthmatic chronic lung diseases. Clinical work-up
included spirometry, fractional exhaled nitric oxide
measurements, skin prick testing, and methacholine challenge.
Eicosanoids were analyzed in EBC by using mass spectrometry
and are reported as concentrations (in picograms per milliliter)
and eicosanoid/palmitic acid (PA) ratios.
Results: Eoxin C4/PA, eoxin D4/PA, eoxin E4/PA, 15-HETE/PA,
and LTC4/PA ratios were significantly increased in asthmatic
versus healthy children. Eoxin D4/PA and LTE4/PA ratios were
also significantly higher in children with BHR. A nonsignificant
trend was observed toward higher eoxin/PA ratios with
increasing asthma severity. In contrast to asthma, children with
chronic lung disease had the highest 15-HETE/PA, LTC4/PA,
LTE4/PA, and LTB4/PA ratios.
Conclusion: The results point to increased activity of the 15-LO
inflammatory pathway in childhood asthma. Mass
spectrometric analyses of EBC demonstrate that increased
eoxin levels not only accompany the increased 5-LO product
LTC4 but are also associated with BHR. These markers might
represent a new therapeutic target for asthma treatment
Integrated care pathways for airway diseases (AIRWAYS-ICPs)
The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers)